Chembio Diagnostics is a diagnostics & research business based in the US. Chembio Diagnostics shares (CEMI) are listed on the NASDAQ and all prices are listed in US Dollars. Chembio Diagnostics employs 188 staff and has a trailing 12-month revenue of around $49.5 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $0.43 |
| 200-day moving average | $0.44 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.72 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Revenue TTM | $49.5 million |
|---|---|
| Gross profit TTM | $3.9 million |
| Return on assets TTM | -18.77% |
| Return on equity TTM | -89.47% |
| Profit margin | -47.03% |
| Book value | $0.49 |
| Market Capitalization | $16.7 million |
TTM: trailing 12 months
We're not expecting Chembio Diagnostics to pay a dividend over the next 12 months.
Chembio Diagnostics's shares were split on a 1:8 basis on 29 May 2012 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Chembio Diagnostics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Chembio Diagnostics shares which in turn could have impacted Chembio Diagnostics's share price.
Over the last 12 months, Chembio Diagnostics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chembio Diagnostics's is 1.8571. This would suggest that Chembio Diagnostics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Chembio Diagnostics, Inc. , together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID 19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, NEXT GENERATION DPP, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.